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Purpose. To assess glutamine/glutamate (Glx) and lactate (Lac)metabolismusing protonmagnetic resonance spectroscopic imaging
(1H-MRS) in order to differentiate between adrenal gland nodules and masses (adenomas, pheochromocytomas, carcinomas,
and metastases). Materials and Methods. Institutional review board approval and informed consent were obtained. A total of
130 patients (47 men) with 132 adrenal nodules/masses were prospectively assessed (54 ± 14.8 years). A multivoxel system was
used with a two-dimensional point-resolved spectroscopy/chemical-shift imaging sequence. Spectroscopic data were interpreted
by visual inspection and peak amplitudes of lipids (Lip), choline (Cho), creatine (Cr), Lac, and Glx. Lac/Cr and Glx/Cr were
calculated. Glx/Cr was assessed in relation to lesion size. Results. Statistically significant differences were observed in Glx/Cr results
between adenomas and pheochromocytomas (𝑃 < 0.05), however, with a low positive predictive value (PPV). Glx levels were
directly proportional to lesion size in carcinomas. A cutoff point of 1.44 was established for the differentiation between carcinomas
larger versus smaller than 4 cm, with 75% sensitivity, 100% specificity, 100% PPV, and 80% accuracy. Lac/Cr results showed no
differences across lesions. A cutoff point of −6.5 for Lac/Cr was established for carcinoma diagnosis. Conclusion. Glx levels are
directly proportional to lesion size in carcinomas. A cutoff point of −6.5 Lac/Cr differentiates carcinomas from noncarcinomas.
1. Introduction
Protonmagnetic resonance spectroscopic imaging (1HMRS)
has become increasingly consolidated as a noninvasive and
risk-free procedure for disease followup [1]. 1H MRS assess-
ment is based onmetabolite levels present in a certain volume
as shown on magnetic resonance imaging (MRI) scans.
In a previous study, we reported our initial experience
in distinguishing adrenal adenomas, pheochromocytomas,
adrenocortical carcinomas, andmetastases based on 1HMRS
data, using histological/computed tomographic findings and
followup data as [2]. Since then, several protocol improve-
ments have been implemented in our institution, which have
allowed the inclusion of new metabolites in the analysis,
namely, lactate (Lac) and the glutamine/glutamate complex
(Glx) [3].
Glucose and glycogen levels are low in tumoral cells.
Therefore, glycolysis regulation in these structure occurs via
alternative carbohydrates, especially glutamine.The degrada-
tion of to lactate has been referred to as glutaminolysis [4].
There is no consensus in the literature regarding the
association between high or low concentrations of glutamine
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Figure 1: T2 HASTE sagittal (left adrenal adenoma): (a) maximun inspiration; (b) maximun expiration; (c) free breathing.
and tumor growth potential [5–7]. Nevertheless, similarly
to glycolysis, the main role of glutaminolysis is to generate
energy, via the production of glutamate, citrate, and aspartate.
One advantage associated with glutaminolysis is that it main-
tains glutamin levels constantly high in cancerous tissues and
solid tumors [4].
Compared with normal cells, tumors use almost all their
ability to degrade glucose, independent of the amount of
oxygen present. However, this consumption under anaerobic
conditions can be up to 20 times higher than in aerobic condi-
tions [8]. In addition, several researchers have demonstrated
that lactate stimulates angiogenesis [9].
1H MRSI in vivo is not able to distinguish between
glutamin and glutamate. As a result, total Glx data are
usually assessed, considering a peak between 2.1 and 2.5 ppm
[1, 10–17]. Notwithstanding, to the authors’ knowledge, no
study so far has assessed glutamine/glutamate metabolism
characteristics in the adrenal gland and correlated these
findings with the possibility to differentiate between nodules
and masses.
Therefore, the objective of this study was to assess Glx
and Lac metabolism using 1H MRS in order to differentiate
between adrenal nodules and masses (adenomas, pheochro-
mocytomas, carcinomas, and metastases).
2. Materials and Methods
The present study was approved by the appropriate Research
Ethics Committee. Informed consent forms were signed by
all patients included or their guardians.
2.1. Patients. A total of 130 patients (47 males) presenting
with adrenal nodules or masses were prospectively assessed.
All patients had been previously examined with a dedicated
adrenal CT and/or a MR protocol. Of the 130 patients, 128
presented nodules ormasses either on the right or left adrenal
gland only, and two presented bilateral masses or nodules,
totaling 132 nodules. All patients underwent 1H MRSI at
the Department of Diagnostic Imaging of our institution.
Data collection took place between January 2004 and May
2011.
The following inclusion criteria were taken into con-
sideration: (1) presenting with adrenal nodule/mass with
a diameter >1.0 cm and previous dedicated adrenal CT or
MRI exam; (2) histopathological confirmation by biopsy or
surgery in cases of pheochromocytomas, carcinomas, func-
tional adenomas, or nonspecific lesions; (3) lesion stability
for over 12 months based on CT or MRI findings in patients
with adenomas. Patients on chemotherapy protocols or with
previous adrenal biopsy or surgery, as well as those in which
it was not possible to schedule the 1H MRSI sequence, were
not included in the sample.
Exclusion criteria were presence of lesion(s) with a
diameter >1.0 cm but no voxel eligible for analysis (consisting
of 100% tumoral tissue), and presence of adrenal nodule or
mass with a diameter around 1.0 cm but presenting surface
contaminants.
Five patients were excluded as a result of poor band
positioning, a low signal-to-noise ratio, and absence of voxels
eligible for analysis. As a result, a total of 125 patients (44
males) met = all study criteria and were therefore included
in the final analysis. Mean age in this group was 54 ±
14.8 years (range: 13–87), and all presented with an adrenal
lesion larger than 1.0 cm (mean ± standard deviation: 4.1 ±
2.68 cm; range: 1.19–14.35 cm). A total of 127 masses were
diagnosed and classified as adenomas (84), carcinomas (10),
pheochromocytomas (28), and metastases (5).
2.2. 1H MRSI Protocol. Patients were examined after a four-
hour fast and 10minutes after the intravenous administration
of an antispasmodic drug (Buscopan). At this occasion,
patients were also asked to answer a questionnaire on MRI
contraindications.
Patients were positioned feet first into the MRI system,
with their arms resting alongside their bodies, and lying
down on their backs on the spine coil. Once the patient was
adequately positioned, the phased-array spine coil was used.
MRI examinations were conducted using either a 1.5 T
Magnetom Sonata scanner (gradient 43mT/m; Siemens
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Figure 2: Final positioning of 1HMRSI scan: (a) T2 HASTE in coronal orientation in the center of the left adrenal adenoma; (b) T2 HASTE
in axial orientation in the center of the left adrenal adenoma; (c) T2 HASTE in sagittal orientation including all adrenal glands, lesions, and
the breathing interval calculated as in Figures 1(a), 1(b), and 1(c).
Table 1: Descriptive analysis of lesions with regard to Glx/Cr and Lac/Cr ratios∗.
Glx/Cr Lac/Cr
Mean ± SD Median Range Mean ± SD Median Range
Adenomas 2.13 ± 1.88 1.69 0–8.77 −3.39 ± 7.12 0 −38.84–1.72
Pheochromocytomas 1.37 ± 1.20 1.13 −1–4.05 −4.64 ± 5.88 −2.5 −22.9–0.93
Carcinomas 2.65 ± 2.82 1.55 0.56–8.2 −10.8 ± 6.34 −9.04 −21.9–−2.56
Metastases 1.95 ± 1.44 1.70 0.12–4.1 −3.62 ± 2.98 −4.23 −7.3–0
Glx/Cr: glutamine/glutamate-creatine ratio; Lac/Cr: lactate-creatine ratio; SD: standard deviation.
∗All comparisons resulted nonsignificant (𝑃 > 0.01).
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Figure 3: Number of masses and nodules according to nodule size.
Medical Systems, Erlangen, Germany), a 1.5 T Magnetom
Espree scanner (33mT/m; Siemens Medical Systems) (𝑛 =
123), or a 3.0 T Magnetom Verio scanner (Siemens Medical
Systems) (𝑛 = 4).
MRI imaging was performed at the level of the adrenal
mass and consisted of T2-weighted half-Fourier acquisition
single shot turbo spin echo (HASTE) sequences and T1-
weighted chemical shift imaging (CSI).
HASTE sequences were performed in three orthogonal
planes to allow three-dimensional (3D) mass location and
thus planning of the shimming and 1H MRSI protocol, as
described by Faria et al. [2].
Subsequently, spectroscopic imaging data were obtained
using a multivoxel system in the selection of the volume
of interest and a hybrid two-dimensional point resolved
spectroscopy (PRESS)/CSI sequence, commercially available
from Siemens Medical Systems. During examination we
reinforce for the patient to breathe smoothly. This protocol
was adopted so as to minimize any possible artifacts from
periadrenal structures.
1HMRSI data were obtained using T2-weighted HASTE
sequences, in two stages: (1) sagittal images only, at maxi-
mum inspiration, maximum expiration, and free breathing,
carefully positioning themultivoxel volume of interest grid in
the center of the lesion, based on all three sagittal sequences
(Figure 1), to include asmuch of the lesion area as possible (or
the whole lesion and part of adjacent fat tissue, if possible),
and (2) three orthogonal planes at expiration, in order to
determine voxel size and to activate only the coil located near-
est to themass/nodule under analysis, as well as to adequately
position outer volume saturation bands (Figure 2).
Six 30mm wide saturation bands were used, positioned
around the adrenal gland, thus minimizing possible field
heterogeneity effects caused by magnetic interference of air
present in the lung parenchyma, bone structures, periadrenal
fat, and fluids present in the biliary tree and kidneys.
Adrenal 1H MRSI images were obtained using a voxel
size of 0.56–3.38 cm3, a field of view of 100–150 cm, 4–8
excitations, repetition time of 1500ms, an echo time of 135ms,
and a delta factor of −3.4, k-space elliptical. Image acquisi-
tion lasted between 7 minutes and 11 minutes 45 seconds.
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Figure 4: Spectroscopic findings: (a) adenomas; (b) metastases; (c) pheochromocytomas; (d) carcinomas. Cho, Cr, Lip, Glx, Lac, and H
2
O
peaks are indicated.
Water suppression was used during spectroscopic examina-
tion so that the lipids present in the gland would bemeasured
on the images (MEGA technique) [17].
2.3. Spectroscopic Data Analysis. All spectroscopic findings
were analyzed by two investigators (Homero J. F. Melo and
Suzan M. Goldman) until consensus was reached. Images
were processed using a Leonardoworkstation (SiemensMed-
ical Systems). A 1000Hz Gaussian line-broadening filter was
used, and priority was given to the transformation of Fourier
data into two spatial directions, using a Hamming filter.
The 1HMRSImatrix was adjusted to the three orthogonal
planes obtained during image acquisition, and the most
appropriate voxels were selected for analysis. Voxels located
in the adjacent fat tissue (not including lesion tissue) were
disconsidered. Spectroscopic analysis was conducted in
left-right, craniocaudal direction. Following voxel selection,
the abscissa was enlarged so that an adequate ppm amplitude
(0.5–8.5) could be used to phase correct water peak in
relation to other metabolites. Subsequently, the ppm range
was reduced (0.5–4.7) again in order to increase spectral
resolution.
All spectroscopic data were interpreted by means of
visual inspection and by measuring peak amplitudes of the
metabolites of interest, namely, creatine (Cr), lactate (Lac),
glutamine, and glutamate (Glx) (2.1–2.5 ppm).
In addition, Glx and Lac were measured in the 2.1–
2.5 ppm range and 1.33 ppm, respectively, and their relation-
ship with Cr (Glx/Cr and Lac/Cr) was calculated.The associ-
ation between Glx-Cr ratios and lesion size was also assessed.
2.4. Statistical Analysis. Data were analyzed using Excel and
BioEstat 4.0 software for themetabolic characterization of the
four types of masses or nodules analyzed, namely, adenomas,
carcinomas, pheochromocytomas, and metastases. Central
tendency (mean and mode) and dispersion values (stan-
dard deviation and range) were calculated for each group.
Student’s t-test for paired samples was used to compare mean
metabolic ratios obtained in the groups, and the chi-square
test was used to correlate differences in the relationships,
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Figure 5: Receiver operating characteristic curve calculated for
Glx/Cr between adenomas and pheochromocytomas.
followed by Yates’ correction or Fisher’s exact test for cell
values below five.
The association between Glx-Cr ratios and nodule size
was assessed using Pearson’s linear correlation. Also, receiver
operating characteristic (ROC) curves were used to deter-
mine cutoff points, sensitivity, specificity, positive predictive
value (PPV), and accuracy were calculated for the cutoff
points established. Significance was set at 𝑃 ≤ 0.05.
3. Results
1H MRSI was successfully performed in 127 (96.2%) of the
132 adrenal masses and nodules assessed. Figure 3 shows the
types and sizes of lesions identified.
Figure 4 shows spectroscopic findings of the nodules
assessed.
Table 1 shows the results obtained for Glx/Cr and Lac/Cr
ratios in the lesions assessed.
Statistically significant differences were observed in
Glx/Cr results between adenomas and pheochromocytomas
(𝑃 < 0.05), however, with a low PPV. The ROC curve
calculated did not reveal a cutoff point that could allow
adequate differentiation between these two types of lesions
(57.1% sensitivity, 66.7% specificity, 36.37%PPV, and a 64.30%
accuracy for a Glx-Cr ratio ≥1.25) (Figure 5). In the other
groups, it was not possible to establish a cutoff point based
on Glx/Cr results.
Glx levels were found to be directly proportional to lesion
size in carcinomas. Figure 6 shows ROC curves calculated for
Glx/Cr in carcinomas, pheochromocytomas, and adenomas
in relation to lesion size (masses or nodules larger versus
smaller than 4 cm). Statistically significant findings were
observed for carcinomas (𝑃 < 0.05), but not for the other two
lesions. A cutoff point of 1.44 was established for the differen-
tiation between carcinomas larger versus smaller than 4 cm
(Figure 6(c)), with 75% sensitivity, 100% specificity, 100%
PPV, and 80% accuracy. Metastases were not included in this
analysis because of the small number of specimens available.
Lac/Cr was also calculated for the different types of
lesions in an attempt to define a cutoff point for differen-
tiation. However, no significant differences were found in
the comparison of adenomas versus nonadenomas (𝑃 =
0.063; 81% sensitivity, 63% specificity). Conversely, we did
observe a tendency toward increased Lac concentrations in
nonadenomas.
The ROC curve calculated for differentiating between
adenomas and nonadenomas shown in Figure 7(a) yielded a
cutoff point of −0.76, with 81.4% sensitivity, 63.1% specificity,
53.8% PPV, and 69.3% accuracy. Student’s 𝑡 test did not reveal
statistically significant differences (𝑃 = 0.063), despite a
trend toward differentiation. The ROC curve for adenomas
and carcinomas (Figure 7(b)) determined a cutoff point of
−4.25, with 90% sensitivity, 76.2% specificity, 30.96% PVV,
and 77.66% accuracy. Conversely, the ROC curve for the dif-
ferentiation between pheochromocytomas and carcinomas,
shown in Figure 7(c), yielded a cutoff point of −6.56, with
80% sensitivity, 71.4% specificity, 49.95% PPV, and 73.66%
accuracy. Finally, the ROC curve for the differentiation
between metastases and carcinomas (Figure 7(d)) resulted in
a cutoff point of −5.34, with 80% sensitivity, 80% specificity,
66.63% PPV, and 80% accuracy.
Because all comparisons in carcinoma lesions yielded
statistically significant differences, a cutoff point was calcu-
lated with the ROC curve for the differentiation between
carcinomas and noncarcinomas (𝑃 < 0.05) (Figure 8),
namely −6.5.
4. Discussion
The present study tested the effectiveness of an 1H MRSI
protocol in differentiating between adrenal masses and
nodules (adenomas, pheochromocytomas, carcinomas, and
metastases) based on the previously tested Lac/Cr andGlx/Cr
ratios.
The first studies using 1H MRSI to assess the adrenal
gland in vivo were aimed at locating the region of inter-
est using spectroscopic images [18]. Although those early
resultswere satisfactory, some limitations of themethodology
deserve to be mentioned: the impossibility to build spectral
graphs, mass/nodule visualization in one single orthogonal
plane only, low magnetic field power, and visualization of
water and fat tissues only. In 2009, Kim et al. proposed the
use of respiratory-triggered proton single-voxel MR spec-
troscopy in vivo for adrenal gland investigation [19]. Again,
early results were promising, but the limitations inherent to
single-voxel MRI weakened overall findings and conclusions.
In an attempt to overcome such limitations, two-dimen-
sional multivoxel systems started to be used to locate and
select the spectroscopic region of interest, starting from
6 BioMed Research International
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Figure 6: Receiver operating characteristic curves calculated for Glx/Cr according to lesion size: (a) adenomas, (b) pheochromocytomas,
and (c) carcinomas. (d) Box plot showing variations in carcinoma lesion size.
the sagittal plane of the adrenal gland [2]. Inmultivoxel image
acquisition, the exact location of the lesion becomes less
important, as more relevant information is provided regard-
ing the tumor’s spatial extent and metabolic heterogeneity
[20].
The present study describes some changes made to
the 1H MRSI acquisition and analysis protocol originally
proposed [2]. Among image acquisition improvements, it
is possible to mention free multivoxel angulation, a better
adjustment of the field of view to the mass or nodule under
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Figure 7: Receiver operating characteristic curves calculated for Lac/Cr between the following groups: (a) adenomas versus nonadenomas;
(b) carcinomas versus adenomas; (c) carcinomas versus pheochromocytomas; and (d) metastases versus carcinomas.
analysis and a better signal-to-noise ratio, in addition to
the two-dimensional sequence adopted. Conversely, the use
of three sagittal planes (maximum inspiration, maximum
expiration, and free breathing), with a limited shimming
area, was maintained, as the authors believe that this strategy
compensates the absence of respiratory monitoring in
multivoxel sequences.
Whole-body scanners with a magnetic field strength
of 3 T are becoming more and more available to the sci-
entific and clinical communities [21]. The advantages of
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spectroscopy at higher field strengths aremainly an increased
signal/noise ratio (SNR), improved spectral, spatial, and tem-
poral resolution, including detection of resonances obscured
at 1.5 T (such as amino acids), and enhancement of J-coupled
spectral resolution [22].
With regard to image analysis, changes made to the pro-
tocol reflect the technological improvements incorporated
by the spectroscopic systems themselves (Siemens Medical
Systems). In particular, the possibility to use different scales,
from higher (0.5–8.5 ppm) to lower (0.5–4.7 ppm) amplitude
values, allowed to better adjust the base line, taking into
consideration peak amplitude measurements calculated for
water and other metabolites in the automatic and manual
determination of spectral phase and frequency. Whenever
necessary, amplitude values were lowered to 2.5–3.5 ppm to
improve the visualization of Cho and Cr peaks, and voxel size
was increased or decreased according to lesion size. All these
strategies contributed to a faster and safer selection of eligible
voxels.
Moreover, adrenal oncocytoma does not follow the rule
of four: (a) 4% diagnosed on CT, (b) 4% of these tumors are
pheochromocytoma or adrenocortical carcinoma, (c) ≥4 cm
in size is an indication for surgery, and (d) 4 years of followup
is required [23].
High Glx and Lac peaks were observed, and therefore
their relationships with Cr were assessed. Both metabolites
showed a great variance across the different lesions analyzed.
The analysis did not reveal statistically significant associations
between Glx/Cr and different types of masses/nodules, but
rather with lesion size: a cutoff point of 1.44 was established
for the differentiation between carcinomas larger versus
smaller than 4 cm; no differences were observed in other
lesions. Although the number of carcinomas included in our
analysis was small (only 10 lesions), our results gain impor-
tance if we take into consideration the very low prevalence of
this type of tumor in the general population [5].
Conversely, Lac/Cr did not show statistically significant
differences in the differentiation between adenomas and
nonadenomas (𝑃 = 0.063). Notwithstanding, the follow-
ing cutoff points could be established: adenomas versus
carcinomas (−4.25), pheochromocytomas versus carcinomas
(−6.56), and carcinomas versus metastases (−5.34) (𝑃 <
0.05). A cutoff point of −6.5 for Lac/Cr was established for
the diagnosis of carcinomas. These findings therefore add to
the existing literature, and especially to our previous study [2]
and contribute to clinical practice by improving our capacity
to accurately diagnose and differentiate between these types
of tumor.
Some limitations of the present study deserve to be
mentioned. First of all, as a result of the strict inclusion
criteria adopted, our sample included a very small number
of metastases (only five), preventing the inclusion of this
category in the statistical analyses. Another limiting factor is
the reduced number of patients using a 3.0 T scanner, render-
ing impossible comparisons between the curves generated by
different fields. Finally, our two examiners had experience in
spectroscopy, and maybe readings made by less experienced
examiners could yield different results. This potential limi-
tation is important because spectroscopic analysis of adrenal
masses is still gaining space, especially if compared with areas
in which it is highly consolidated, such as prostate cancer.
Future studies are warranted to investigate the possibil-
ity of differentiation between functional and nonfunctional
adenomas, still a major difficulty in the management of
these patients, as well as to compare in vivo and in vitro
spectroscopic findingswith the aimof identifyingmetabolites
present in different masses.
In sum, the 1H MRSI sequences adopted in the present
study proved effective for the differentiation between adrenal
masses and nodules and data analysis was effective and
reliable. Other studies are currently underway that focus on
lipid concentrations as observed on spectral graphs compared
with laboratory tests.
Our main findings can be summarized as follows: Glx
levels are directly proportional to lesion size in carcinomas,
and Lac/Cr allows to differentiate between carcinomas and
noncarcinomas.
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